Recent Analysts’ Ratings Changes for AbbVie (ABBV)

AbbVie (NYSE: ABBV) has recently received a number of price target changes and ratings updates:

• 6/27/2026 – AbbVie was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 6/23/2026 – AbbVie had its “market perform” rating reaffirmed by Sanford C. Bernstein.
• 6/23/2026 – AbbVie had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 6/23/2026 – AbbVie had its price target raised by Canaccord Genuity Group Inc. from $265.00 to $273.00. They now have a “buy” rating on the stock.
• 6/23/2026 – AbbVie had its “overweight” rating reaffirmed by Piper Sandler. They now have a $298.00 price target on the stock.
• 6/22/2026 – AbbVie was given a new $260.00 price target by Wells Fargo & Company.
• 6/8/2026 – AbbVie had its “hold (c)” rating reaffirmed by Weiss Ratings.
• 6/7/2026 – AbbVie was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 5/30/2026 – AbbVie was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 5/17/2026 – AbbVie was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 5/15/2026 – AbbVie was given a new $235.00 price target by Evercore Inc.
• 5/14/2026 – AbbVie had its price target raised by Piper Sandler from $294.00 to $298.00. They now have an “overweight” rating on the stock.
• 5/9/2026 – AbbVie was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 5/1/2026 – AbbVie had its “buy” rating reaffirmed by Guggenheim. They now have a $249.00 price target on the stock.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Wednesday, July 15th. AbbVie’s dividend payout ratio is presently 340.89%.

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.